Esab Corp Reports Results For The Quarter Ended June 30: Earnings Summary
ESAB Corp reports results for the quarter ended June 30 - Earnings Summary
ESAB Corp ESAB.N reported quarterly adjusted earnings of $1.33 per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $1.36. The mean expectation of ten analysts for the quarter was for earnings of $1.38 per share. Wall Street expected results to range from $1.30 to $1.43 per share.
Revenue rose 12.9% to $807.63 million from a year ago; analysts expected $758.01 million.
ESAB Corp's reported EPS for the quarter was 50 cents.
The company reported quarterly net income of $32.35 million.
ESAB Corp shares had fallen by 6.2% this quarter and lost 17.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 6.9% in the last three months.
In the last 30 days, four analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the industrial machinery & equipment peer group is also "buy"
Wall Street's median 12-month price target for ESAB Corp is $136.00, about 32% above its last closing price of $92.47
This summary was machine generated from LSEG data August 6 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 1.38 | 1.33 | Missed |
Mar. 31 2026 | 1.34 | 1.31 | Missed |
Dec. 31 2025 | 1.34 | 1.35 | Beat |
Sep. 30 2025 | 1.27 | 1.32 | Beat |
Recent news on ESAB
See all newsBrief: ESAB Corp - Declares QTRLY Cash Dividend Of $0.12 Per Share
Esab Corp Reports Results For The Quarter Ended June 30: Earnings Summary
ESAB Corp beats Q2 sales estimates, raises FY core net sales growth
U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation
Brief: Esab - Appoints Mitchell P. Rales As Executive Chair Effective June 10, 2026 - SEC Filing